Intersect ENT expects to grow its revenue in 2021 compared to 2019, according to its preliminary fourth-quarter revenue report for last year.
Four takeaways:
1. Preliminary and unaudited revenue for the fourth quarter is in the range of $27.7 million to $28.1 million.
2. Sinuva had a quarterly revenue of about $2.5 million.
3. Vensure initiated U.S. sales with revenue of approximately $300,000.
4. Cash, cash equivalents and restricted cash were expected to be approximately $105 million as of Dec. 31, 2020.
Intersect ENT's full fourth-quarter report is expected March 9.